Cargando…

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer

BACKGROUND: Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohan, Riche, Kneebone, A., Eade, T., Hsiao, E., Emmett, L., Brown, Christopher, Hunter, J., Hruby, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394924/ https://www.ncbi.nlm.nih.gov/pubmed/37528487 http://dx.doi.org/10.1186/s13014-023-02302-8

Ejemplares similares

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
por: Sadetski, Igor, et al.
Publicado: (2021)

Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
por: Sabbagh, Ali, et al.
Publicado: (2022)

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer
por: Azzam, Gregory, et al.
Publicado: (2015)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Metabolic response after 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases prostate cancer
por: Gawish, Ahmed, et al.
Publicado: (2022)

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy
por: Bell, Linda J., et al.
Publicado: (2021)

Correction to: Metabolic response after 68 Ga‑PSMA‑PET/CT‑directed IGRT/SBRT for oligometastases prostate cancer
por: Gawish, Ahmed, et al.
Publicado: (2023)

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Locoregional control and survival after lymph node SBRT in oligometastatic disease
por: Loi, Mauro, et al.
Publicado: (2018)

PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer
por: Pastorello, Edoardo, et al.
Publicado: (2023)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Pelvic salvage (SBRT) radiotherapy based on (68)Ga-PSMA PET/CT: About a case
por: Slaoui, A., et al.
Publicado: (2019)

Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments
por: Navarria, Pierina, et al.
Publicado: (2014)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy
por: Gawish, Ahmed, et al.
Publicado: (2022)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
por: Gerum, Sabine, et al.
Publicado: (2018)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
por: Wegner, Rodney E., et al.
Publicado: (2019)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response
por: van Gysen, Kirsten, et al.
Publicado: (2018)

Implementing daily soft tissue image guidance with reduced margins for post‐prostatectomy radiotherapy: research‐based changes to clinical practice
por: Bell, Linda J., et al.
Publicado: (2019)

SBRT treatment of abdominal and pelvic oligometastatic lymph nodes using ring‐mounted Halcyon Linac
por: Pokhrel, Damodar, et al.
Publicado: (2021)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

Initial experience with intra‐fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment
por: Bell, Linda J., et al.
Publicado: (2017)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f02103a3kjt4qd7gogfanf93a6